ImmunoGen, Inc. (NASDAQ:IMGN – Get Free Report) SVP Stacy Ann Coen sold 78,223 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $16.05, for a total transaction of $1,255,479.15. Following the completion of the sale, the senior vice president now owns 36,966 shares of the company’s stock, valued at approximately $593,304.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
ImmunoGen Stock Performance
NASDAQ:IMGN opened at $16.11 on Friday. ImmunoGen, Inc. has a 1 year low of $3.61 and a 1 year high of $20.69. The firm’s fifty day simple moving average is $15.08 and its 200 day simple moving average is $15.80. The company has a current ratio of 5.70, a quick ratio of 5.65 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $4.29 billion, a PE ratio of -51.97 and a beta of 0.83.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Putnam Investments LLC grew its stake in ImmunoGen by 2.7% in the 1st quarter. Putnam Investments LLC now owns 1,151,153 shares of the biotechnology company’s stock valued at $4,420,000 after buying an additional 29,841 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in ImmunoGen in the 2nd quarter valued at $150,000. Artisan Partners Limited Partnership acquired a new position in ImmunoGen in the 1st quarter valued at $12,216,000. Bank of New York Mellon Corp boosted its holdings in ImmunoGen by 39.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,092,993 shares of the biotechnology company’s stock valued at $20,625,000 after purchasing an additional 310,960 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in ImmunoGen by 7.2% in the 2nd quarter. Mackenzie Financial Corp now owns 17,853 shares of the biotechnology company’s stock valued at $336,000 after purchasing an additional 1,200 shares during the period. 90.50% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
ImmunoGen Company Profile
ImmunoGen, Inc, a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
- Five stocks we like better than ImmunoGen
- What Does the Consumer Price Index Measure?
- MarketBeat Week in Review – 11/13 – 11/17
- Insider Trades May Not Tell You What You Think
- 3 large caps with red hot RSIs with upside
- Options Trading – Understanding Strike Price
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.